Know Cancer

or
forgot password

The Effect of Blood Glucose to Different Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes


N/A
18 Years
75 Years
Open (Enrolling by invite only)
Both
Gastric Cancer

Thank you

Trial Information

The Effect of Blood Glucose to Different Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes


Different digestive tract reconstruction will affect the blood glucose level of gastric
cancer with type 2 diabetes. Subtotal gastrectomy with Billroth II reconstruction and total
gastrectomy with Roux-en-Y reconstruction may help to improve glycaemic control which
includes fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, C
-peptide and body weight of gastric cancer patients with type 2 diabetes.

The investigators will observed fasting blood glucose, postprandial blood glucose,
glycosylated hemoglobin, C -peptide and body weight of the patients preoperation, 14 days
postoperation 3 month and 6month postoperation. The investigators will observed the effect
of blood glucose to different digestive tract reconstruction after gastrectomy of gastric
cancer with type 2 diabetes


Inclusion Criteria:



1. 18-75 years old,gastric cancer ,can be performed operation

2. with type 2 diabetes,fasting blood glucose > 6.1mmol/L

3. without serious underlying diseases which may affect the metabolism and nutrient
uptake

4. without serious underlying diseases which may affect anesthesia and operation

5. can be performed subtotal or total gastrectomy, predicted survival period > 6months

6. no other abdominal operation

7. preoperation consultation

8. informed consent

Exclusion Criteria:

1. recurrent,metastasis or die

2. patient requests for quit

3. pregnancy

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Principal Investigator

Zhao Yan, Doctor

Investigator Role:

Study Director

Investigator Affiliation:

Tianjin Medical University Cancer Institute and Hospital

Authority:

China: Food and Drug Administration

Study ID:

CIH-WXN-201205001

NCT ID:

NCT01637350

Start Date:

August 2012

Completion Date:

December 2014

Related Keywords:

  • Gastric Cancer
  • Diabetes Mellitus, Type 2
  • Stomach Neoplasms

Name

Location